Nilotinib Zentiva (Nilotinib)

Nilotinib blocks the ATP‑binding site of the BCR‑ABL fusion protein, preventing the enzyme from phosphorylating downstream targets. This inhibition stops the signaling pathways that promote uncontrolled cell division, leading to reduced proliferation and increased apoptosis of malignant leukemic cells.

The prescribed dose of Nilotinib Zentiva is set by the treating physician based on the specific indication, disease phase, patient weight, renal and hepatic function, and any concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s clinical judgment.

Safety data for nilotinib in pregnancy and lactation are limited. The drug is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception.

To order Nilotinib Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor, offering higher potency and activity against many imatinib‑resistant mutations. Compared with imatinib, nilotinib often achieves faster and deeper molecular responses, but it may carry a higher risk of cardiovascular and metabolic side effects, requiring different monitoring.

Store Nilotinib Zentiva at room temperature, below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and avoid storing in humid or excessively hot environments to maintain product stability.

Nilotinib Zentiva is taken orally, usually twice daily on an empty stomach, with at least one hour before or two hours after a meal. The tablets should be swallowed whole with water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include QT interval prolongation leading to potentially life‑threatening arrhythmias, severe liver injury, pancreatitis, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should report any chest pain, palpitations, jaundice, severe abdominal pain, or skin rash promptly to their physician.

Nilotinib should be avoided in patients with a known hypersensitivity to nilotinib or any component of the formulation, those with uncontrolled cardiac disease, significant QT prolongation, or severe hepatic impairment. It is also contraindicated in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustments.